Alembic Pharma gets USFDA nod for anti-depression drug
New Delhi: Alembic Pharmaceuticals has received the US health regulator's nod for Bupropion Hydrochloride tablets, used for the treatment of the major depressive disorder.
"The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride tablets," Alembic Pharmaceuticals said in a BSE filing.
The approval is for strengths of 75 mg and 100 mg.
The approved product is therapeutically equivalent to the reference listed drug product (RLD) Wellbutrin tablets of GlaxoSmithKline LLC.
Quoting IMS December 2017 data, the company said Bupropion Hydrochloride tablets had an estimated market size of USD 37 million.
The company now has a total of 72 ANDA approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd